Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gin Hwa BiotechROCO:7806 22 Net Margin % is 10.77% as of Dec. 2025, which is 40% below its 10-year median of 17.88. GuruFocus rates ROCO:7806 with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Gin Hwa Biotech ranks better than 83.01% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Gin Hwa Biotech's Net Income for the
six
months ended in Dec. 2025 was NT$27.4 Mil. Gin Hwa Biotech's Revenue for the
six
months ended in Dec. 2025 was NT$254.5 Mil. Therefore, Gin Hwa Biotech's net margin for the quarter that ended in Dec. 2025 was 10.77%.
The historical rank and industry rank for Gin Hwa Biotech's Net Margin % or its related term are showing as below:
ROCO:7806'
s Net Margin % Range Over the Past 10 Years
Min: 13.99 Med: 17.88 Max: 21.24
Current: 13.99
ROCO:7806's Net Margin % is ranked better than 83.01% of 942
companies
in the Biotechnology industry
Industry Median: -88.295
vs ROCO:7806: 13.99
Gin Hwa Biotech (ROCO:7806) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Gin Hwa Biotech Net Margin % Related Terms
Gin Hwa Biotech Net Margin % Historical Data
* Premium members only.
The historical data trend for Gin Hwa Biotech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7806 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Gin Hwa Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gin Hwa Biotech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gin Hwa Biotech's Net Margin % distribution charts can be found below:
* The bar in red indicates where Gin Hwa Biotech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gin Hwa Biotech (ROCO:7806) has a Net Margin % of 10.77% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Gin Hwa Biotech and its competitors. This is 40% below median its historical median of 17.88. Over the past decade, Gin Hwa Biotech's Net Margin % has ranged from 13.99 to 21.24. According to the industry distribution chart, Gin Hwa Biotech ranks #160 out of 942 companies in the Biotechnology industry, placing it in the top 17%.
Is Gin Hwa Biotech's Net Margin % too high?
Gin Hwa Biotech's current Net Margin % of 10.77% is 40% below median its 10-year median of 17.88. Over the past 10 years, this metric has ranged from a low of 13.99 to a high of 21.24. Based on the distribution chart, Gin Hwa Biotech ranks #160 out of 942 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Gin Hwa Biotech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Gin Hwa Biotech's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gin Hwa Biotech ranks #160 out of 942 companies for Net Margin %. This places Gin Hwa Biotech in the top 17% of its industry — outperforming the majority of peers. Historically, Gin Hwa Biotech's own Net Margin % has ranged from 13.99 to 21.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Gin Hwa Biotech and its competitors. Gin Hwa Biotech's current Net Margin % is 10.77%, which is 40% below median its own 10-year median of 17.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gin Hwa Biotech stock overvalued right now?
Gin Hwa Biotech (ROCO:7806) has a current Net Margin % of 10.77%. The current Net Margin % is 10.77%, which is 40% below median its 10-year median of 17.88. Gin Hwa Biotech's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Gin Hwa Biotech (ROCO:7806), the current Net Margin % is 10.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gin Hwa Biotech Inc is engaged in developing completely original products to achieve every vision. Its Services and technology are Product Development, OEM Service, Core Technology, R & D Center, Professional Production, and Others.
22GF Score
Get the complete analysis for ROCO:7806
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7806 has been successfully added to your 
